Atara Biotherapeutics, Inc. (0HIY)
London Stock Exchange · UK · prices in USD · close of 27 Oct 2026
Key indicators
| Last close | USD 8.140 |
|---|---|
| 52-week range | 4.018 – 19.050 |
| Return, 1 month / 3 months | −3.4% / +3.2% |
| Return, 1 year / 3 years | −47.2% / −74.9% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 38 |
| Volatility (1 year) | 151.8% |
| Worst drawdown (1 year) | -78.1% |
| Average daily value traded | 0.01M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Atara Biotherapeutics is a biotechnology company based in South San Francisco that develops off-the-shelf T-cell immunotherapies. Its work centres on treatments for cancers and autoimmune conditions driven by the Epstein-Barr virus, including a therapy for a rare complication that can follow organ or bone marrow transplantation. The company also pursues cell therapy candidates aimed at solid tumours and autoimmune disease, and it works with academic and clinical partners to advance these programmes.
Atara Biotherapeutics, Inc. trades under the code 0HIY on the London Stock Exchange in UK, with its price quoted in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Atara Biotherapeutics, Inc. (0HIY) trades on the London Stock Exchange in UK. It last closed at USD 8.140 on 27 October 2026.
Its price-based Market X-Ray is 34 out of 100 (a weak price profile), ranking 2,910 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 47.2% and over the last three months it rose 3.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 57 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 6.1% | ||
| From 52-week high | -56.1% | ||
| Momentum | 56 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 3.2% | ||
| 6-month return | 67.1% | ||
| 12-month return, skipping the last month | -45.4% | ||
| Stability (higher is calmer) | 3 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 151.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -78.1% | ||
| Liquidity | 11 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −10.9% |
|---|---|
| 1 month | −3.4% |
| 3 months | +3.2% |
| 6 months | +67.1% |
| 1 year | −47.2% |
| 3 years | −74.9% |
| 5 years | −97.8% |
Signals
| 50-day / 200-day average | 9.211 / 7.670 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.604 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.